Radixin (RDX) is a membrane-cytoskeletal linker protein that plays a crucial role in binding actin filaments to the plasma membrane and organizing cellular junctions. RDX is involved in multiple cellular processes including protein localization to the plasma membrane, regulation of adherens junction organization, and establishment of endothelial barriers 1. The protein is particularly important in vascular endothelial cells, where it participates in immune response and cell proliferation signaling pathways 1. RDX also functions in glucocorticoid-regulated actin cytoskeleton remodeling in the brain 2. In disease contexts, RDX expression and stability are dysregulated in gastric cancer. Intercellular adhesion molecule 2 (ICAM2) suppresses gastric cancer progression by promoting ubiquitination-mediated RDX degradation through the NEDD4L E3 ligase pathway, reducing RDX protein stability and expression 3. Additionally, RDX has been identified as a high-hazard prognostic gene in breast cancer PANoptosis-associated pathway analysis, where elevated RDX expression correlates with worse prognosis 1. RDX mutations are associated with autosomal recessive deafness (DFNB24), highlighting its essential role in stereocilium organization at the cellular periphery. Under hyperglycemic conditions affecting vascular smooth muscle cells, RDX expression is altered through NOTCH3/RANBP1 axis regulation 4.